CH
ZYNE

Canton Hathaway’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Canton Hathaway’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$5K – 332
2021
Q1 		$5K Buy
+1,000
New +$4.53K ﹤0.01% 298

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Canton Hathaway's ZYNE Position: Q2 2021 in Review

Canton Hathaway sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2021, closing a stake of 1,000 shares — an estimated $5K sold.

Canton Hathaway first reported a position in ZYNE in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 65 funds tracked by Wall St. Rank hold ZYNE as of Q2 2021.

  • Canton Hathaway reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2021 after selling out during the quarter.
  • Canton Hathaway sold 1,000 Zynerba Pharmaceuticals, Inc shares in Q2 2021, an estimated $5K.
  • Canton Hathaway first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2021 and held it in 1 quarter.
  • Canton Hathaway's Zynerba Pharmaceuticals, Inc position peaked at $5K in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2021.

Based on Canton Hathaway's 13F filing for Q2 2021, filed 8 Jul 2021.